Skip to Content

Isturisa Approval History

FDA Approved: Yes (First approved March 6, 2020)
Brand name: Isturisa
Generic name: osilodrostat
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Cushing's Syndrome

Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease.

Development History and FDA Approval Process for Isturisa

DateArticle
Mar  8, 2020Approval FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide